|
| Press Releases |
|
 |
|
| Monday, October 17, 2022 |
|
|
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval |
| Novotech, the leading Asia Pacific biotech specialist CRO, and Endpoints News present a webinar for biotechs considering the clinical research opportunities in Asia Pacific and the regulatory pathways to achieving FDA approval. more info >> |
|
| Wednesday, October 12, 2022 |
|
|
Novotech India Recognised as "Best Workplaces for Women 2022" by Global Work Standards Authority |
| Novotech, the leading Asia Pacific biotech specialist CRO, has again received "Best Workplace" certification by the leading workplace culture organization Great Place to Work Institute. Novotech's India team has received a Best Workplaces for Women 2022 recognition and listed in the Top 75 organisations in India recognised for excelling people practices, responsiveness to feedback and a culture of openness and diversity. more info >> |
|
| Friday, October 7, 2022 |
|
|
Novotech Selected as Scrip Awards Finalist for Best Full-Service CRO |
| Novotech, the leading Asia Pacific biotech specialist CRO, joins a prestigious group of global CROs as a finalist in the Scrip Award for Best Full-Service CRO. This year the Award has been split into two categories to separate the full-service providers from the smaller CROs. more info >> |
|
| Thursday, September 15, 2022 |
|
|
Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference |
| Novotech, the leading Asia Pacific biotech specialist CRO, has been awarded the Cell & Gene Therapy Clinical Trials award at the 6th Cell & Gene Therapy World Asia 2022 conference. more info >> |
|
| Monday, September 5, 2022 |
|
|
Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC |
| Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology drugs. more info >> |
|
| Friday, September 2, 2022 |
|
|
APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report |
| Novotech, the leading Asia Pacific biotech specialist CRO has released new market data in a report now available titled "Evolution of Clinical Trials in the Asia Pacific Region". The report was prepared by GlobalData and confirms that "the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period." more info >> |
|
| Monday, July 25, 2022 |
|
|
Novotech's Flexible Work Policy is Finalist in Best Workplace Flexibility Program "Excellence Award 2022" |
| Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, has been recognised for its innovative approach to workplace flexibility. more info >> |
|
| Monday, July 18, 2022 |
|
|
Novotech and Endpoints Present "Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T" |
| Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, is pleased to present an Endpoints webinar on CAR-T therapy in China - the current landscape and future opportunities. more info >> |
|
| Wednesday, July 13, 2022 |
|
|
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea |
| Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK bioscience on the recent COVID-19 vaccine licence approval. more info >> |
|
| Wednesday, June 29, 2022 |
|
|
Novotech Receives "Best Biologics CRO Award 2022" at Korea Bioprocessing Excellence Awards 2022 |
| Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, was today awarded the Best Biologics CRO Award at a ceremony as part of 11th Biologics Manufacturing Korea, the 6th Cell & Gene Therapy World East Asia, and the 3rd BioLogistics World Korea conferences (29th - 30th June 2022) which attract more than 300 representatives from Korea's top biopharmas, vaccine manufacturers, and biologics companies. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Wintermar Offshore (WINS:JK) Reports 1H2025 Results
Jul 30, 2025 19:56 HKT/SGT
|
|
|
Hong Kong Shopping Festival Returns in August with Bigger and Better 2nd Edition
Jul 30, 2025 18:29 HKT/SGT
|
|
|
Production, Sales and Export Results for June, 2025
Jul 30, 2025 18:24 JST
|
|
|
Sales, Production, and Export Results for the First Half of 2025
Jul 30, 2025 18:06 JST
|
|
|
Introducing the Meshy 5 Preview: Smarter AI, Cleaner Models, Bigger Animation Potential 
Jul 30, 2025 17:00 JST
|
|
|
Ongoing Share Buybacks Demonstrate Confidence, Shoucheng Holdings Boosts Market Expectations with Concrete Action
Jul 30, 2025 11:00 HKT/SGT
|
|
|
Collaborative Development of Ultra-Compact and Lightweight Satellite Communication User Terminals for Mobility with Mitsubishi Chemical, NICT, and TECHLAB
Jul 30, 2025 11:00 JST
|
|
|
Naoris Protocol Announces Upcoming TGE for $NAORIS
Jul 29, 2025 23:59 HKT/SGT
|
|
|
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Jul 29, 2025 23:13 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Concludes Agreement with Modius to Provide DCIM Solutions for Data Centers Worldwide
Jul 29, 2025 20:00 JST
|
|
|
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
Jul 29, 2025 16:00 HKT/SGT
|
|
|
Set at the Osaka-Kansai Expo venue! Detailed program announced for the "OSAKA JAPAN SDGs Forum"
Jul 29, 2025 14:30 JST
|
|
|
GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year
Jul 29, 2025 13:15 HKT/SGT
|
|
|
Unitree Races Toward IPO as Robot Applications Accelerate: Shoucheng Holdings Unlocks Dual-Engine Gains
Jul 29, 2025 11:30 HKT/SGT
|
|
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
Jul 29, 2025 9:01 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
